Long-Term Outcomes of Pegcetacoplan for GA Show Promise Long-Term Outcomes of Pegcetacoplan for GA Show Promise
Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Ophthalmology News Source Type: news
More News: Drugs & Pharmacology | Opthalmology